About HLA class II histocompatibility antigen, DO alpha chain
HLA class II histocompatibility antigen, DO alpha chain (HLA-DOA) is a protein
from Homo sapiens identified by UniProt accession
P06340, 250 residues long.
MolForge cross-references it against 0 known binders and
109 disease associations.
Target properties
| Protein name | HLA class II histocompatibility antigen, DO alpha chain |
|---|
| UniProt accession | P06340 |
|---|
| Gene | HLA-DOA |
|---|
| Organism | Homo sapiens |
|---|
| Length | 250 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (109)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.43
- chronic hepatitis B virus infection · score 0.25
- platelet count · score 0.24
- white wine liking measurement · score 0.23
- coronary artery disease · score 0.16
- total blood protein measurement · score 0.12
- immune deficiency, familial variable · score 0.04
- hyper-IgM syndrome type 3 · score 0.04
- hyper-IgM syndrome type 2 · score 0.03
- hyper-IgM syndrome type 5 · score 0.03
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P06340-F1 | alphafold | PREDICTED | 89.37 | — |
Amino-acid sequence (250 residues)
MALRAGLVLG FHTLMTLLSP QEAGATKADH MGSYGPAFYQ SYGASGQFTH EFDEEQLFSV DLKKSEAVWR LPEFGDFARF DPQGGLAGIA AIKAHLDILV ERSNRSRAIN VPPRVTVLPK SRVELGQPNI LICIVDNIFP PVINITWLRN GQTVTEGVAQ TSFYSQPDHL FRKFHYLPFV PSAEDVYDCQ VEHWGLDAPL LRHWELQVPI PPPDAMETLV CALGLAIGLV GFLVGTVLII MGTYVSSVPR
Explore HLA class II histocompatibility antigen, DO alpha chain with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets